WASHINGTON, DC – Yesterday, the FDA announced updates to how and where the medication abortion drug, mifepristone, can be dispensed to patients. Advocates have long pushed for the drug to be more accessible and celebrate the decision by the FDA to ease unnecessary restrictions that create barriers to abortion care. This decision follows the temporary easing of in-person requirements during the COVID-19 public health emergency (PHE). Medication abortion is a safe, effective way to end an early pregnancy and has been FDA approved in the United States for over 20 years.
“The longstanding prior rule placed unnecessary barriers to medication abortion care,” said Fabiola Carrión
, Director, Reproductive and Sexual Health. “Removing in-person dispensing requirements for mifepristone will protect patient privacy, and lessen the burdens of travel, childcare, lodging costs, and missed work, all of which occur disproportionately among Black, Indigenous, and other People of Color, people who live in rural areas, and those struggling economically. Modernizing this rule absolutely makes sense, as it will be particularly beneficial for individuals who have low incomes or are underserved. As longtime Medicaid advocates, we also call on the Centers for Medicare & Medicaid Services (CMS) to issue guidance
to ensure that people enrolled in Medicaid have access to mifepristone per the new FDA guidelines.”
Abortion is health care. Period. The National Health Law Program works at every level to protect access to the full range of essential reproductive health services, including abortion, in Medicaid, the Affordable Care Act (ACA) Marketplaces, and private insurance. Learn more at healthlaw.org/abortion-is-health-care.